Abstract
Abstract: :
Purpose:To evaluate short term the effect on visual acuity and fluorescein angiograph changes of photodynamic therapy with Veteporfin for CNV subfoveal in patients with AMD Vs other causes (pathologic myopia, angioid streak and idiopathics) from January 2001 to December 2001. Methods:Prospective, nonrandomized and comparative study. 14 patients from Retina department to the Fundación Hospital de la Luz, México city, were included with CNV subfoveal. The patients were divided into two groups. Group I of 7 patients (7 eyes) with CNV subfoveal secondary AMD and Group II with CNV secondary to other causes. We recorded visual acuity, fluorescein angiography were performed at the time of the first examination and every 45 days for 3 months. We included patients with visual acuity = 20/80 or worst, CNV subfoveal <50% classic component, CNV less than 5400. All patients received two treatments regimens with Veteporfin. Results:Veteporfin therapy was well tolerated in both groups: Group I with CNV secondary AMD. Visual Acuity: 2 patients (28.5%) improvement l line, l patient (14.2%) improvement 2 lines, 4 patients (57.1) not improvement, their visual acuity were maintained. Group II ( 5 pathologic myopia, 1 angioid streak, and 2 idiopathic).Visual Acuity: 2 patients (28.5%) improvement l line, l patient (14.2%) improvement 4 lines, 3 patient (42.8%) improved 2 lines, l patient (14.24%) not improvement, their visual acuity were maintained. Fluorescein Angiography: Group I, 4 patients (57%) absence of leakage, l patient (14.2%) area of leakage decreased, 2 patients (28.5%) progression of leakage.Group II, 5 patients (71.4%) provided absence of leakage, l patient (14.2%) area of leakage decreased, l patient (14.2%) area of leakage stabilizes. Conclusion:The prognosis of visual acuity and fluorescein angiography in patients with Veteporfin therapy with CNV not related to AMD was much better than CNV related to AMD. Repeated verteporfin therapy demonstrated effective and selective occlusion on CNV. If not conclusive for the number of treated eyes the result of this report suggest the need to continue with others studies with more patients .
Keywords: 353 clinical (human) or epidemiologic studies: outcomes/complications • 460 macula/fovea • 308 age-related macular degeneration